Authors: Chen J, Zhang W, Yan H, Chen J, Liu H, Zhou X, Zhang H, Cheng D.
DOI: 10.3389/fmolb.2025.1718941
Abstract Summary
Researchers developed a post-translational modification (PTM)-based gene signature that predicts survival in osteosarcoma patients. High-risk scores correlated with immunosuppressive tumor environments enriched in regulatory immune cells and reduced anti-tumor responses. The gene GRN emerged as a key driver, promoting cancer cell growth, spread, and immune evasion. GRN silencing impaired osteosarcoma cell proliferation and invasion, positioning it as a promising therapeutic target.
Why Brain? ðŸ§
PTM-based gene signature predicts osteosarcoma survival and reveals immunosuppressive tumor environment, identifying GRN as a key driver of cancer progression and potential therapeutic target.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
